References
1. Stoltz DA, Meyerholz DK, Welsh MJ. Origins of cystic fibrosis lung disease. The New England journal of medicine.2015;372(4):351-362.
2. Hoegger MJ, Fischer AJ, McMenimen JD, et al. Cystic fibrosis. Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. Science. 2014;345(6198):818-822.
3. Birket SE, Chu KK, Liu L, et al. A Functional Anatomic Defect of the Cystic Fibrosis Airway. American journal of respiratory and critical care medicine. 2014.
4. Regnis JA, Robinson M, Bailey DL, et al. Mucociliary clearance in patients with cystic fibrosis and in normal subjects. American journal of respiratory and critical care medicine. 1994;150(1):66-71.
5. Flume PA, Robinson KA, O’Sullivan BP, et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respiratory care. 2009;54(4):522-537.
6. Ward N, Stiller K, Holland AE, Australian Cystic Fibrosis Exercise Survey g. Exercise is commonly used as a substitute for traditional airway clearance techniques by adults with cystic fibrosis in Australia: a survey. J Physiother. 2019;65(1):43-50.
7. Hoo ZH, Daniels T, Wildman MJ, Teare MD, Bradley JM. Airway clearance techniques used by people with cystic fibrosis in the UK.Physiotherapy. 2015;101(4):340-348.
8. Dwyer TJ, Daviskas E, Zainuldin R, et al. Effects of exercise and airway clearance (positive expiratory pressure) on mucus clearance in cystic fibrosis: a randomised crossover trial. The European respiratory journal. 2019;53(4).
9. McIlwaine MP, Lee Son NM, Richmond ML. Physiotherapy and cystic fibrosis: what is the evidence base? Current opinion in pulmonary medicine. 2014;20(6):613-617.
10. Oates GR, Stepanikova I, Rowe SM, Gamble S, Gutierrez HH, Harris WT. Objective Versus Self-Reported Adherence to Airway Clearance Therapy in Cystic Fibrosis. Respiratory care. 2019;64(2):176-181.
11. Mikesell CL, Kempainen RR, Laguna TA, et al. Objective Measurement of Adherence to Out-Patient Airway Clearance Therapy by High-Frequency Chest Wall Compression in Cystic Fibrosis. Respiratory care.2017;62(7):920-927.
12. Benoit CM, Christensen E, Nickel AJ, et al. Objective Measures of Vest Therapy Adherence Among Pediatric Subjects With Cystic Fibrosis.Respiratory care. 2020;65(12):1831-1837.
13. Szczesniak RD, Li D, Su W, et al. Phenotypes of Rapid Cystic Fibrosis Lung Disease Progression during Adolescence and Young Adulthood. American journal of respiratory and critical care medicine. 2017;196(4):471-478.
14. O’Sullivan KJ, Collins L, McGrath D, Linnane B, O’Sullivan L, Dunne CP. Oscillating Positive Expiratory Pressure Therapy May Be Performed Poorly by Children With Cystic Fibrosis. Respiratory care.2019;64(4):398-405.
15. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. The New England journal of medicine. 2011;365(18):1663-1672.
16. Rowe SM, Daines C, Ringshausen FC, et al. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis. The New England journal of medicine. 2017;377(21):2024-2035.
17. Taylor-Cousar JL, Munck A, McKone EF, et al. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. The New England journal of medicine. 2017;377(21):2013-2023.
18. Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet.2019;394(10212):1940-1948.
19. Middleton PG, Mall MA, Drevinek P, et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. The New England journal of medicine.2019;381(19):1809-1819.
20. Donaldson SH, Laube BL, Corcoran TE, et al. Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR. JCI insight. 2018;3(24).
21. Adam RJ, Hisert KB, Dodd JD, et al. Acute administration of ivacaftor to people with cystic fibrosis and a mutation reveals smooth muscle abnormalities. JCI insight. 2016;1(4):e86183.
22. Gifford AH, Mayer-Hamblett N, Pearson K, Nichols DP. Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.2020;19(5):762-767.
23. Sole A, Olveira C, Perez I, et al. Development and electronic validation of the revised Cystic Fibrosis Questionnaire (CFQ-R Teen/Adult): New tool for monitoring psychosocial health in CF.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 2018;17(5):672-679.
24. Schneiderman-Walker J, Wilkes DL, Strug L, et al. Sex differences in habitual physical activity and lung function decline in children with cystic fibrosis. The Journal of pediatrics. 2005;147(3):321-326.
25. Valencia-Peris A, Lizandra J, Moya-Mata I, Gomez-Gonzalvo F, Castillo-Corullon S, Escribano A. Comparison of Physical Activity and Sedentary Behaviour between Schoolchildren with Cystic Fibrosis and Healthy Controls: A Gender Analysis. International journal of environmental research and public health. 2021;18(10).
26. Rowbotham NJ, Smith SJ, Davies G, et al. Can exercise replace airway clearance techniques in cystic fibrosis? A survey of patients and healthcare professionals. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 2020;19(4):e19-e24.
27. Doull I. Cystic fibrosis 2019: Year in review. Paediatric respiratory reviews. 2020;35:95-98.
28. Ding S, Zhong C. Exercise and Cystic Fibrosis. Advances in experimental medicine and biology. 2020;1228:381-391.
29. Ward N, Morrow S, Stiller K, Holland AE. Exercise as a substitute for traditional airway clearance in cystic fibrosis: a systematic review. Thorax. 2020.
30. Morrison L, Milroy S. Oscillating devices for airway clearance in people with cystic fibrosis. The Cochrane database of systematic reviews. 2020;4:CD006842.
31. Wilson LM, Morrison L, Robinson KA. Airway clearance techniques for cystic fibrosis: an overview of Cochrane systematic reviews. The Cochrane database of systematic reviews. 2019;1:CD011231.
32. Fischer AJ, Singh SB, LaMarche MM, et al. Sustained Coinfections with Staphylococcus aureus and Pseudomonas aeruginosa in Cystic Fibrosis. American journal of respiratory and critical care medicine. 2020.
33. Porterfield HS, Maakestad LJ, LaMarche MM, et al. MRSA Strains with Distinct Accessory Genes Predominate at Different Ages in Cystic Fibrosis. Pediatric pulmonology. 2021.